You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Enhancing Outcomes in Patients With Myeloproliferative Neoplasms: Practical Application for Nurses

  • Authors: Patricia Manea, BSN, RN, CCRP
  • CE Released: 10/14/2020
  • Valid for credit through: 10/14/2021
Start Activity

Target Audience and Goal Statement

This activity is intended for oncology nurses and other clinicians involved in the care of patients with myeloproliferative neoplasms.

The goal of this activity is to improve oncology nurses' ability to differentiate among myeloproliferative neoplasms (MPNs), personalize treatment options, monitor for and treat adverse events, and provide appropriate counseling in order to enhance outcomes for patients with MPNs.

Upon completion of this activity, participants will:

  • Increased knowledge regarding the
    • Emerging MPN treatments
  • Greater competence related to
    • Discussing the potential side effects of MPN treatment options with patients
    • Mitigating common treatment-related adverse effects in patients with MPNs
  • Demonstrating greater confidence in their ability to
    • Providing key counseling points to patients with MPNs about their treatment


As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


  • Patricia Manea, BSN, RN, CCRP

    Project Manager, Hematology and Phase I Clinical Trials
    UT Health San Antonio MD Anderson Cancer Center
    San Antonio, Texas


    Disclosure: Patricia Manea, BSN, RN, CCRP, has disclosed no relevant financial relationships.


  • Davecia R. Cameron, MS

    Medical Education Director, Medscape, LLC


    Disclosure: Davecia R. Cameron, MS, has disclosed no relevant financial relationships.

CE Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Enhancing Outcomes in Patients With Myeloproliferative Neoplasms: Practical Application for Nurses

Authors: Patricia Manea, BSN, RN, CCRPFaculty and Disclosures

CE Released: 10/14/2020

Valid for credit through: 10/14/2021


AE = adverse event
ASA = acetylsalicylic acid
ASH = American Society of Hematology
basos = basophils
BAT = best available therapy
BID = twice daily
BM = bone marrow
BMBx = bone marrow biopsy
CBC = complete blood count
CAD = coronary artery disease
CHF = congestive heart failure
CHR = complete hematologic response
CI = clinical improvement
CI = confidence interval
CML = chronic lymphocytic leukemia
CMR = complete molecular response
CR = complete response
CT = computed tomography
CV = cardiovascular
CVA = cerebrovascular accident
D/C = discontinuation
DIPSS = Dynamic International Prognostic Scoring System
DIPSS-Plus = Dynamic International Prognostic Scoring System-Plus
DM = diabetes mellitus
DVT = deep vein thrombosis
ELN = European LeukemiaNet
EMH = extramedullary hematopoiesis
eos = eosinophils
EPO = erythropoietin
ESA = erythropoiesis-stimulating agents
ET = essential thrombocythemia
FDA = US Food and Drug Administration
FEDR = fedratinib
FU = follow-up
GERD = gastroesophageal reflux disease
GI = gastrointestinal
Hep B = hepatitis B
HCP = healthcare provider
HCT = hematopoietic cell transplantation
Hct = hematocrit
Hgb = hemoglobin
HTN = hypertension
HR = hazard ratio
HSC = hematopoietic stem cell
HSCT = hematopoietic stem cell transplantation
HSV = herpes simplex virus
HU = hydroxyurea
IFN = interferon
IMiD = immunomodulatory drug
IPSET = International Prognostic Score for Thrombosis in Essential Thrombocythemia
IPSS = International Prognostic Scoring System
ITT = intent to treat
IWG-MRT = International Working Group-Myeloproliferative Neoplasms Research and Treatment
JAKi = JAK inhibitor
LCM = left costal margin
LDH = lactate dehydrogenase
LE = lower extremity
LFT = liver function test
LLS = Leukemia & Lymphoma Society
LMWH = low-molecular-weight heparin
lymph = lymphocytes
MDS = myelodysplastic syndrome
MF = myelofibrosis
MI = myocardial infarction
MNC = mononuclear cells
MOA = mechanism of action
monos = monocytes
MPD = myeloproliferative disorder
MPN = myeloproliferative neoplasm
MPN-SAF = Myeloproliferative Neoplasm Symptom Assessment Score
MRD = minimal residual disease
MRI = magnetic resonance imaging
NA = not applicable
NCCN = National Comprehensive Cancer Network
NGS = next-generation sequencing
OS = overall survival
PAC = pacritinib
PB = peripheral blood
PCP = primary care provider
PCR = polymerase chain reaction
PE = pulmonary embolism
plt = platelet
PMF = primary myelofibrosis
PMHx = past medical history
PMN = polymorphonuclear leukocyte
PR = partial response
PRBC = packed red blood cell
PS = performance status
PTX-2 = pentraxin-2
PV = polycythemia vera
QD = every day
QoL = quality of life
R = randomized
RBC = red blood cell
rINFa = recombinant interferon alfa
ropeg = ropeginterferon alfa-2b
RPSFT = rank-preserving structural failure time
RR = relative risk
RUX = ruxolitinib
ruxo = ruxolitnib
SC = subcutaneous
SOC = standard of care
SVR = splenic volume reduction
SVRR = splenic volume reduction rate
TB = tuberculosis
TEAE = treatment-emergent adverse event
TRAE = treatment-related adverse event
TSS = total symptom score
ULN = upper limit of normal
UNL = upper normal limit
URI = upper respiratory infection
UTI = urinary tract infection
VAF = variant allele frequency
VWD = von Willebrand disease
VZV = varicella-zoster virus
WBC = white blood cell
WHO = World Health Organization

« Return to: Enhancing Outcomes in Patients With Myeloproliferative Neoplasms: Practical Application for Nurses
  • Print